Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

NRAC: an emerging nutrient-responsive regulator of tissue-specific fatty acid metabolism

Zhang R.

Narrative Review on Systemic / IV, published in Biochem Biophys Res Commun (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biochem Biophys Res Commun (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42224826
PMCID
PMC13270263
DOI
10.1016/j.bbrc.2026.154057

Abstract (original English)

Fatty acid (FA) uptake is coordinated across tissues to maintain metabolic homeostasis, yet the mechanisms underlying tissue-specific regulation remain incompletely understood. NRAC has emerged as a nutrient-responsive, tissue-restricted factor enriched in adipose tissue and heart in both mice and humans. Mouse studies show that Nrac is dynamically regulated by feeding, fasting, and obesity in a tissue-specific manner. Recent work further shows that NRAC interacts with CD36 to regulate CD36-dependent FA uptake in adipocytes. Physiological studies support a role for NRAC in adipose lipid handling and systemic FA homeostasis, while human data link adipose NRAC expression to body fat distribution and circulating lipid traits. Together, current evidence identifies NRAC as an emerging regulator of tissue-specific FA metabolism and cardiometabolic health.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MyocardiumAdipose TissueAnimalsHumansMiceObesityFatty AcidsLipid MetabolismCD36 AntigensNutrients

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research